Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03850912 · ClinicalTrials.gov registry record · NA
Symptom Management Implementation of Patient Reported Outcomes in Oncology
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 42,808
- Enrollment target
NCT03850912: Completed NA study, sponsored by Dana-Farber Cancer Institute.
NCT03850912 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 42,808 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (2951% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03850912, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 42,808 participants
- Enrollment target
Study Summary
Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize symptom control. Growth in Internet access and proliferation of smartphones has created an opportunity to re-engineer cancer care delivery. Electronic symptom tracking and feedback is a promising strategy to improve symptom control. Electronic patient reported outcome (ePRO) monitoring of cancer symptoms has been shown to decrease symptom burden, improve quality of life, reduce acute care and even extend survival. SIMPRO will use functioning ePRO prototypes to create and refine the electronic symptom management system eSyM
Primary Outcome
The primary study outcome of the stepped wedge cluster RCT (randomized controlled trial) is the EDTR rate. This outcome will be defined in relation to the date of discharge from hospital (surgical cohort) or the initiation date of a new intravenous chemo regimen (medical oncology cohort). This is a binary outcome and we will analyze the absolute difference and odds ratio for the medical oncology and surgical cohorts combined and independently.
Interventions
- OTHER Qualitative Interview
- OTHER Stakeholder Survey (Control Period)
- OTHER Stakeholder Survey (Intervention Period)
- OTHER SASS Questionnaire
- OTHER eSyM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42,808 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2025-06-09 |
| Phase | NA |
What the finished NCT03850912 record still lists
NCT03850912 is an interventional study that assigns participants to a tested intervention. Its 42,808 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (2951% higher).
The record links to 0 conditions, and to 5 interventions - of which Qualitative Interview is the first listed.
NCT03850912 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03850912 about?
NCT03850912 is a clinical study titled "Symptom Management Implementation of Patient Reported Outcomes in Oncology". Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize symptom control. Growth in Internet access and proliferation of smartphones...
What is the current status of trial NCT03850912?
This trial is currently completed. It is a NA study. The enrollment target is 42,808 participants. The study started on 2019-07-25. Estimated completion is 2025-06-09.
What interventions are being tested in trial NCT03850912?
The interventions under investigation include: Qualitative Interview (OTHER), Stakeholder Survey (Control Period) (OTHER), Stakeholder Survey (Intervention Period) (OTHER), SASS Questionnaire (OTHER), eSyM (OTHER).
Who is sponsoring clinical trial NCT03850912?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03850912's enrollment target sits among peer trials
42,808 7th of 2000 higher than 1,994 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05607732 · 45,257 participants · NA
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
- NCT06824350 · 45,450 participants · NA
Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
- NCT04994756 · 40,000 participants
Stroke Thrombectomy and Aneurysm Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI